ChromaDex Corporation ( CDXC ) NASDAQ Capital Market

Cena: 7.87 ( -0.88% )

Aktualizacja 03-18 21:00
NASDAQ Capital Market
Branża: Biotechnology
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:
An error occurred: DataFrame is empty. Check the ticker or date range.

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 106
Giełda: NASDAQ Capital Market
Ilość akcji w obrocie: 59%
Ilość akcji: 75 124 400
Debiut giełdowy: 2008-06-25
WWW: https://www.chromadex.com
CEO: Mr. Robert N. Fried
Adres: 10900 Wilshire Boulevard
Siedziba: 90024 Los Angeles
ISIN: US1710774076
Opis firmy:

Chromadex Corporation działa jako firma Bioscience, która koncentruje się na zdrowym starzeniu się. Firma działa w trzech segmentach: produkty konsumenckie; Składniki; oraz analityczne standardy i usługi referencyjne. Bada dinukleotyd adeniny nikotynamidowej (NAD+); Zapewnia gotowe produkty suplementów diety, które zawierają zastrzeżone składniki bezpośrednio konsumentom, a także dystrybutorom; oraz opracowuje i komercjalizuje oparte na zastrzeżonych technologiach składników i dostarcza te składniki jako surowce producentom produktów konsumenckich. Firma komercjalizuje również rybozyd nikotynamidu NAD+ jako flagowy składnik Niagen; Niagen jako aktywny składnik produktów konsumenckich pod nazwą Tru Niagen; i Immulina, lipoproteiny typu Brauna, w tym ekstrakty spiruliny i związki aktywne, które są używane do wspierania ludzkiej funkcji immunologicznej. Oferuje również analityczne standardy i usługi referencyjne obejmujące dostawę produktów w celu przeprowadzenia kontroli jakości surowców i produktów konsumenckich w suplementach dietetycznych, kosmetykach, żywności i napojach, nauk przyrodniczych i branż farmaceutycznych. Firma dystrybuuje produkty Tru Niagen bezpośrednio do konsumentów za pośrednictwem swojej prawidłowej platformy e-commerce Trunigen.com, Amazon i innych rynków internetowych, a także specjalistycznych sprzedawców detalicznych i bezpośrednich praktyków opieki zdrowotnej w Stanach Zjednoczonych. Chromadex Corporation ma siedzibę w Los Angeles w Kalifornii.

Wskaźniki finansowe
Kapitalizacja (USD) 611 895 648
Aktywa: 56 522 000
Cena: 7.87
Wskaźnik Altman Z-Score: 11.8
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: 71.5
Ilość akcji w obrocie: 59%
Średni wolumen: 809 373
Ilość akcji 77 750 400
Wskaźniki finansowe
Przychody TTM 101 008 000
Zobowiązania: 22 153 000
Przedział 52 tyg.: 2.305 - 9.18
Piotroski F-Score: 6
Umiarkowany (średnia jakość finansowa)
EPS: 0.1
P/E branży: 26.1
Beta: 1.88
Raport okresowy: 2025-05-06
WWW: https://www.chromadex.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Robert N. Fried Chief Executive Officer & Director 768 957 1960
Mr. Frank Louis Jaksch Jr. Co-Founder & Chairman 70 000 1968
Ms. Brianna Gerber Executive Officer 482 155 1981
Mr. James Lee Chief Financial Officer, Principal Accounting Officer & Controller 0 1975
Kendall Knysch Head of Media Relations & Partnerships 0 0
Dr. Andrew Shao Ph.D. Senior Vice President of Global Regulatory & Scientific Affairs 0 0
Mr. Carlos Lopez Senior Vice President & General Counsel 0 0
Alex Worsham Vice President of Global Marketing & Communications 0 0
Mr. David Kroes Senior Vice President of People Matters 0 0
Ms. Chu Yan Managing Director of Asia Pacific 0 0
Wiadomości dla ChromaDex Corporation
Tytuł Treść Źródło Aktualizacja Link
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today confirmed it has changed its corporate name to Niagen Bioscience, Inc. (“Niagen Bioscience” or the “Company”) and the Company's common stock will begin trading under the new Nasdaq symbol “NAGE” at stock market open today, Wednesday, March 19, 2025. The CUSIP number for the Company's. businesswire.com 2025-03-19 10:34:00 Czytaj oryginał (ang.)
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 LOS ANGELES--(BUSINESS WIRE)---- $CDXC #InvestorRelations--ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it will change its corporate name to Niagen Bioscience, Inc. and trade under the new Nasdaq symbol “NAGE” effective at stock market open on Wednesday, March 19, 2025. As part of this transition, the Company will deploy a follow-up announcement with additional updates regarding the name change, rebrand, an. businesswire.com 2025-03-13 10:34:00 Czytaj oryginał (ang.)
ChromaDex to Present at the 37th Annual Roth Conference LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announces that senior management will participate at the 37th Annual ROTH Conference. ChromaDex CEO, Rob Fried, will participate on the Longevity and Supplementation Panel on Monday, March 17, at 12:00 PM PT (3:00 PM ET). Panels will be livestreamed and available at https://wsw.com/webcast/roth50. Additionally, ChromaD. businesswire.com 2025-03-11 18:04:00 Czytaj oryginał (ang.)
ChromaDex Capitalizes On Longevity Boom But Valuation Remains High ChromaDex Corporation shows strong revenue growth and profitability, driven by its NAD+ precursors and flagship product Niagen, despite high valuation and execution risks. Record-breaking financial performance includes a 37.41% revenue increase, $7.2 million net income, and expanded gross margins, with a significant e-commerce boost. The company faces challenges like supply chain issues, tariff risks, and regulatory uncertainties, which could impact its ambitious growth targets and market position. seekingalpha.com 2025-03-06 12:30:33 Czytaj oryginał (ang.)
ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript ChromaDex Corporation (NASDAQ:CDXC ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Ben Shamsian - Vice President, Lytham Partners, Investor Relations Rob Fried - Chief Executive Officer Ozan Pamir - Chief Financial Officer Andrew Shao - SVP, Scientific & Regulatory Affairs Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Mitchell Pinheiro - Sturdivant Bill Dezellem - Tieton Capital Management Ram Selvaraju - H.C. Wainwright Sean McGowan - ROTH Capital J.P. seekingalpha.com 2025-03-04 22:53:47 Czytaj oryginał (ang.)
ChromaDex (CDXC) Q4 Earnings and Revenues Surpass Estimates ChromaDex (CDXC) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to break-even earnings per share a year ago. zacks.com 2025-03-04 20:15:22 Czytaj oryginał (ang.)
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results. Fourth Quarter 2024 Total net sales of $29.1 million, with $22.7 million from Tru Niagen®, up 37% and 29%, respectively, from the prior year quarter. Posted strong gross margin of 62.5%, up 150 basis points from 61.0% in the prior year quarter. General and administrative expense decreased $4.4 million, which includes a $3.5 million reversal of previously accrued roy. businesswire.com 2025-03-04 18:02:00 Czytaj oryginał (ang.)
Pick These 4 Stocks With Solid Net Profit Margin to Boost Return Let's take a look at four stocks, GFF, BGC, CHX and CDXC, with impressive net profit margins for a robust portfolio. zacks.com 2025-02-20 11:05:25 Czytaj oryginał (ang.)
ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announced that it will participate in a webcasted company presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025. The company presentation will take place at 12:00 p.m. ET on Monday, January 13, 2025. The webcast can be accessed directly at https://lytham. businesswire.com 2025-01-06 10:32:00 Czytaj oryginał (ang.)
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025. zacks.com 2024-12-24 14:51:19 Czytaj oryginał (ang.)
ChromaDex (CDXC) is on the Move, Here's Why the Trend Could be Sustainable If you are looking for stocks that are well positioned to maintain their recent uptrend, ChromaDex (CDXC) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. zacks.com 2024-12-09 11:50:19 Czytaj oryginał (ang.)
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) proudly announces its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc.'s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made an impact on their industries and society at large. This recognition underscores ChromaDex's industry-leading NAD+ research and its expanding portfolio of healthy aging products featuring Niagen® (patented nicoti. businesswire.com 2024-12-03 10:34:00 Czytaj oryginał (ang.)
ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run? ChromaDex (CDXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com 2024-11-22 12:16:13 Czytaj oryginał (ang.)
Recent Price Trend in ChromaDex (CDXC) is Your Friend, Here's Why ChromaDex (CDXC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. zacks.com 2024-11-21 11:50:23 Czytaj oryginał (ang.)
ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, announces that its flagship patented nicotinamide riboside (NR) ingredient, Niagen®, is the hero ingredient in Longevity.Technology's inaugural supplement called Longevity.Technology® LONGEVITY. Designed to support a healthier, longer life, the supplement includes Niagen, the gold standard ingredient for enhancing NAD+ level. businesswire.com 2024-11-14 10:32:00 Czytaj oryginał (ang.)
What Makes ChromaDex (CDXC) a Strong Momentum Stock: Buy Now? Does ChromaDex (CDXC) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com 2024-11-08 15:01:11 Czytaj oryginał (ang.)
5 Stocks With Recent Price Strength to Tap Wall Street Rally Investors target stocks that are witnessing a bull run. Some of the stocks seeing price strength are CDXC, SEZL, TILE, BGC, CORT. zacks.com 2024-11-08 10:10:35 Czytaj oryginał (ang.)
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the nationwide rollout of its pharmaceutical-grade nicotinamide riboside chloride (NRC) products, Niagen® IV, now accessible at over 200 Restore Hyper Wellness locations across the United States. This represents a major milestone, making Niagen IV—a significant advancement in intravenous NAD+ therapy—more widely acc. businesswire.com 2024-11-07 10:32:00 Czytaj oryginał (ang.)
ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue? ChromaDex (CDXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com 2024-11-05 12:16:12 Czytaj oryginał (ang.)
ChromaDex (CDXC) Is a Great Choice for 'Trend' Investors, Here's Why ChromaDex (CDXC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. zacks.com 2024-11-05 11:51:38 Czytaj oryginał (ang.)
ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript ChromaDex Corporation (NASDAQ:CDXC ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Ben Shamsian - IR Rob Fried - CEO Ozan Pamir - CFO Andrew Shao - SVP, Scientific & Regulatory Affairs Wesley Yu - VP, Finance Conference Call Participants Jeff Cohen - Ladenburg Thalmann & Co. Edward Marks - H.C. Wainwright Bill Dezellem - Tieton Capital Management Sean McGowan - ROTH MKM Partners J.P. seekingalpha.com 2024-11-01 16:48:09 Czytaj oryginał (ang.)
ChromaDex (CDXC) Beats Q3 Earnings and Revenue Estimates ChromaDex (CDXC) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.01 per share a year ago. zacks.com 2024-10-31 20:20:38 Czytaj oryginał (ang.)
ChromaDex Gears Up to Report Q3 Earnings: Here's What to Expect On CDXC's third-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its marketed product Niagen and updates on the pipeline. zacks.com 2024-10-29 14:46:13 Czytaj oryginał (ang.)
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024 LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it has rescheduled its previously announced conference call to Thursday, October 31, 2024 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on Thursday. businesswire.com 2024-10-28 10:32:00 Czytaj oryginał (ang.)
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024 LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it will hold a conference call on Wednesday, November 6, 2024 at 4:30 p.m. ET. to discuss its financial results for the third quarter, which ended September 30, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on Thursday, October 31, 2024. Investor. businesswire.com 2024-10-24 12:32:00 Czytaj oryginał (ang.)
ChromaDex to Participate in the 17th Annual LD Micro Main Event LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it will be participating at the 17th Annual LD Micro Main Event at the Luxe Sunset Boulevard Hotel, California on October 29th, 2024. The event is expected to feature 150 companies, presenting in half-hour increments, as well as private 1:1 meetings. ChromaDex's Chief Executive Officer, Rob Fried, and Chief Financial. businesswire.com 2024-10-23 12:34:00 Czytaj oryginał (ang.)
Are Medical Stocks Lagging ChromaDex (CDXC) This Year? Here is how ChromaDex (CDXC) and Bioventus (BVS) have performed compared to their sector so far this year. zacks.com 2024-10-18 14:45:38 Czytaj oryginał (ang.)
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN) LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CRN--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced today that Radicle Science and Council for Responsible Nutrition (CRN) honored Yasmeen Nkrumah-Elie, Ph.D, ChromaDex's Global Director of External Research, as the winner of the inaugural Trailblazing Woman Award. “I am deeply honored to receive the Trailblazing Woman Award,” said Dr. Nkrumah-Elie, “and I am moved by the. businesswire.com 2024-10-15 12:32:00 Czytaj oryginał (ang.)
ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on healthy-aging research, today announced that Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, will participate in a fireside chat moderated by Sean McGowan, Senior Analyst at Roth Capital Partners, at the Lytham Partners Fall 2024 Investor Conference. Wesley Yu, Vice President of Finance at ChromaDex, and Mr. Fried will also host virtual one-on-one. businesswire.com 2024-09-26 20:12:00 Czytaj oryginał (ang.)